Clinical data examining the association of PD-L1 expression and EGFR and KRAS biomarkers with survival in NSCLC may help elucidate the interplay between these biomarkers and any potential effect on patient prognosis. The gene discussed is CD274; the disease is non-small cell lung carcinoma.